Professor of Radiation Oncology, University Tex Houston
Radiation Oncology
Dr. Christopher H. Crane, MD
|
|
Give Review
Christopher Crane practices Radiation Oncology. He studied medicine at University of Virginia School of Medicine. He has 3 awards "America's Top Doctors", "Top Doctors:SE Texas" and "America's Top Doctors for Cancer". Christopher Crane is a published doctor. He published 100 publications, including: 'Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Che...'
Publications
- RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncolog...
- Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal.
- Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Approp...
- Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response A...
- Comparison of Locoregional versus Extended Locoregional Radiation Volumes for Patients with Nonmetastatic Gastro-esophageal Junction Carcinomas.
- Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer.
- The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal ca...
- Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum.
- Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal.
- Intraoperative radiation therapy for locally advanced primary and recurrent colorectal cancer: Ten-year institutional experience.
- Erratum to: Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy.
- In Reply to Bahl et al.
- Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial.
- Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival.
- Radiographic Tumor-Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer.
- Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after ...
- Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.
- Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer.
- Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Anal Cancer: Outcomes and Toxicity.
- The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma.
- Metformin use and improved response to therapy in rectal cancer.
- Duodenal Toxicity After Fractionated Chemoradiation for Unresectable Pancreatic Cancer.
- Is Personalization of Care Coming to Pancreatic Oncology?
- Keys to personalized care in pancreatic oncology.
- A High Positive Lymph Node Ratio is Associated with Distant Recurrence after Surgical Resection of Ampullary Carcinoma.
- Relationships Among Body Mass Index, Longitudinal Body Composition Alterations, and Survival in Patients With Locally Advanced Pancreatic Cancer Receiving Chemoradiati...
- Multimodality Therapy Offers a Chance for Cure in Patients with Pancreatic Adenocarcinoma Deemed Unresectable at First Operative Exploration.
- Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators.
- Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer.
- Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy.
- Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.
- Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer.
- Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial.
- Radiation treatment outcomes for unresectable hepatocellular carcinoma.
- Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of...
- Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial.
- Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma.
- Role of Definitive Radiation Therapy in Carcinoma of Unknown Primary in the Abdomen and Pelvis.
- Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma.
- Survival Outcomes in Resected Extrahepatic Cholangiocarcinoma: Effect of Adjuvant Radiotherapy in a Surveillance, Epidemiology, and End Results Analysis.
- Radiation therapy in operable and locally advanced pancreatic cancer.
- Multidetector Computed Tomography Follow-up of Hypoattenuating Small Liver Lesions in Patients With Rectal Cancer.
- Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation.
- Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation.
- Challenges in the study of adjuvant chemoradiation after pancreaticoduodenectomy.
- Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation.
- Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.
- Long-term quality of life after radiotherapy for the treatment of anal cancer.
- Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer.
- Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes.
- Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer.
- Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement.
- Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Ra...
- Is there a role for intraoperative radiation therapy in patients with resected pancreatic adenocarcinoma?
- Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course.
- Staging, prognostic factors, and therapy of localized rectal cancer.
- Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.
- Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma.
- Stereotactic radiotherapy for pancreatic cancer?
- Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival ...
- Improving soft-tissue contrast in four-dimensional computed tomography images of liver cancer patients using a deformable image registration method.
- Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases.
- The added value of multidisciplinary care for patients with pancreatic cancer.
- Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
- Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
- Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer.
- Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy.
- Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery.
- Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.
- Radiotherapy for hepatocellular carcinoma: an overview.
- Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.
- Prognostic factors for squamous cell cancer of the anal canal.
- Proton radiotherapy for liver tumors: dosimetric advantages over photon plans.
- High-dose-rate remote afterloaders for intraoperative radiation therapy.
- Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer.
- Future chemoradiation strategies in pancreatic cancer.
- Predictors and patterns of recurrence after definitive chemoradiation for anal cancer.
- Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or...
- Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
- Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.
- Current treatment for localized anal carcinoma.
- Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer.
- Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy?
- Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer.
- Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
- Potential benefits of integration of therapies with chemoradiation in rectal cancer.
- Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.
- Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
- Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases.
- Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.
- Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma.
- Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
- Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.
- Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision...
- Preoperative and adjuvant treatment of localized rectal cancer.
- Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.
- The promises and potential pitfalls of organ preservation for locally advanced rectal cancer.
- Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.
- Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Che...
Schools
Virginia Commonwealth University School Of Medicine
Roanoke Meml Hospital
University Of Virginia
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
Education
-
University of Virginia -
University of Virginia School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1316032899 | |
| NPPES Provider LastName | CRANE | |
| NPPES Provider FirstName | CHRISTOPHER | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 20.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1316032899 |
| Last Name Of The Provider | CRANE |
| First Name Of The Provider | CHRISTOPHER |
| View All |
Similar Doctors
|
|
Dr. Thomas J. Pugh, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark A. D'Andrea, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel C. Garner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James W. Welsh, MD |
|
|
Dr. Adeel Kaiser, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Beverly A. Guadagnolo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven H. Lin, MD |
|
|
Dr. Henry Mok, MD |
|
|
Dr. John S. Yordy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wendy A. Woodward, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Mark A. Edson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amol J. Ghia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cameron H. Swanick, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Arthur D. Hamberger, MD
This Doctor is OpenDoctor Recommended.
|